Sex assigned at birth may modify health‐related quality of life in children treated with peanut oral immunotherapy
Pediatric Allergy and Immunology · 2025
DOI: 10.1111/pai.70177 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Allergy and Immunology, 2025. Verfasst von Sophie A Rosser und 7 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Immunology, Murdoch Children's Research Institute, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Peanut Hypersensitivity, Quality of Life, Desensitization, Immunologic, Probiotics. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Government Research Training Program (RTP) Scholarship, National Allergy Centre of Excellence Postgraduate Scholarship, Metagenics Australia.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
The high burden of peanut allergy underscores the need for treatment options that improve patient health‐related quality of life (HRQL). However, the modifying effect of sex assigned at birth on treatment‐related outcomes remains poorly understood. We sought to investigate whether sex modifies treatment effect on the change in overall and subdomain HRQL during the PPOIT‐003 trial.
Methods
PPOIT‐003 was a multicenter, randomized controlled trial in 201 children with peanut allergy (aged 1–10) allocated to combined probiotic and peanut oral immunotherapy (PPOIT), peanut oral immunotherapy alone (OIT), or placebo. Participant HRQL was measured with the Food Allergy Quality of Life–Parent Form (FAQLQ‐PF) at baseline, end‐of‐treatment, and 12 months post‐treatment. Multivariable linear regression with an interaction term was used to investigate the relationship between treatment and HRQL in males ( N = 128, 63.68%) and females ( N = 73, 36.32%).
Results
Sex‐modification of total FAQLQ‐PF scores was present between baseline to end of 12 month follow‐up ( p = .008). In this time, improvement in FAQLQ‐PF scores was significantly better in active compared to placebo groups for males (PPOIT vs. Placebo: −1.003 [95% CI: −1.571, −0.436]; OIT vs. Placebo: −1.250 [95% CI: −1.805, −0.695]), but not for females where improvement also occurred in the placebo group (PPOIT vs. Placebo: −0.148 [95% CI: −0.914, 0.617]; OIT vs. Placebo: 0.252 [95% CI: −0.547, 1.052]). Separate analysis of study phases revealed sex effect modification was greater during treatment than during post‐treatment follow‐up in domains related to food anxiety ( p = .037) and emotional impact of allergy ( p = .063).
Conclusion
Sex modifies HRQL outcomes during peanut OIT. Greater understanding of the biological and psychosocial drivers of post‐treatment HRQL will facilitate personalized management approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy Immunology, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
- School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia.
- Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia.
- National Allergy Centre of Excellence (NACE), Parkville, Victoria, Australia.
- Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.
- Department of Allergy and Immunology, The Royal Children's Hospital, Parkville, Victoria, Australia.
ORCID-Profile: Sophie A Rosser, Melanie Lloyd, Paxton Loke, Sarah Ashley
Förderung
- Australian Government Research Training Program (RTP) Scholarship
- National Allergy Centre of Excellence Postgraduate Scholarship
- Metagenics Australia
- Prota Therapeutics
- National Health and Medical Research Council
Zitieren
APA
Rosser, S. A., Lloyd, M., Loke, P., Ashley, S., O'Sullivan, M. D., Quinn, P., Gold, M., & Tang, M. L. K. (2025). Sex assigned at birth may modify health‐related quality of life in children treated with peanut oral immunotherapy. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.70177
Vancouver
Rosser SA, Lloyd M, Loke P, Ashley S, O'Sullivan MD, Quinn P, et al. Sex assigned at birth may modify health‐related quality of life in children treated with peanut oral immunotherapy. Pediatric Allergy and Immunology. 2025. doi:10.1111/pai.70177
BibTeX
@article{Rosser2025,
author = {Rosser, Sophie A and Lloyd, Melanie and Loke, Paxton and Ashley, Sarah and O'Sullivan, Michael D and Quinn, Patrick and Gold, Michael and Tang, Mimi L K},
title = {Sex assigned at birth may modify health‐related quality of life in children treated with peanut oral immunotherapy},
journal = {Pediatric Allergy and Immunology},
year = {2025},
doi = {10.1111/pai.70177}
}
EUVIMED